Company / R&D Expense
Edesa Biotech, Inc. R&D Expense History
FY2014-FY2021 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$3.3M
FY2021
5-year range
$1.0M / $3.3M
FY2017-FY2021
Trend
+203.7%
vs FY2020
Sector context
Sector data unavailable
Latest sector comparison
What the data says
R&D Expense changed +204% YoY in FY2021, a notable deviation from the 6-year average annual change of +32%.
Based on SEC 10-K filings.
$3M in FY2021 with a 5-year CAGR of +6.2%.
Improved from $2M to $3M over the past 3 years.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +19.0%
- 5-Year CAGR
- +6.2%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +6.2%, indicating consistent growth.
- In FY2021, r&d expense increased 203.7% year-over-year.
- Lowest r&d expense in the period was in FY2017.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -0.47 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2021 | $3.3M | +203.7% |
| FY2020 | $1.1M | -44.4% |
| FY2018 | $2.0M | +91.7% |
| FY2017 | $1.0M | -58.1% |
| FY2016 | $2.5M | +21.8% |
| FY2015 | $2.0M | -23.4% |
| FY2014 | $2.6M | - |
As of FY2021 · SEC 10-K · Updated Jun 24, 2026